Single‐cell analysis reveals metastatic cell heterogeneity in clear cell renal cell carcinoma

Renal cell carcinoma (RCC) is one of the leading causes of cancer‐related death worldwide. Tumour metastasis and heterogeneity lead to poor survival outcomes and drug resistance in patients with metastatic RCC (mRCC). In this study, we aimed to assess intratumoural heterogeneity (ITH) in mRCC cells by performing a combined analysis of bulk data and single‐cell RNA‐sequencing data, and develop novel biomarkers for prognosis prediction on the basis of the potential molecular mechanisms underlying tumorigenesis. Eligible single‐cell cohorts related to mRCC were acquired using the Gene Expression Omnibus (GEO) dataset to identify potential mRCC subpopulations. We then performed gene set variation analysis to understand the differential function in primary RCC and mRCC samples. Subsequently, we applied weighted correlation network analysis to identify coexpressing gene modules that were related to the external trait of metastasis. Protein‐protein interactions were used to screen hub subpopulation‐difference (sub‐dif) markers (ACTG1, IL6, CASP3, ACTB and RAP1B) that might be involved in the regulation of RCC metastasis and progression. Cox regression analysis revealed that ACTG1 was a protective factor (HR < 1), whereas the other four genes (IL6, CASP3, ACTB and RAP1B) were risk factors (HR > 1). Kaplan‐Meier survival analysis suggested the potential prognostic value of these sub‐dif markers. The expression of sub‐dif markers in mRCC was further evaluated in clinical samples by immunohistochemistry (IHC). Additionally, the genetic features of sub‐dif marker expression patterns, such as genetic variation profiles, correlations with tumour‐infiltrating lymphocytes (TILs), and targeted signalling pathway activities, were assessed in bulk RNA‐seq datasets. In conclusion, we established novel subpopulation markers as key prognostic factors affecting EMT‐related signalling pathway activation in mRCC, which could facilitate the implementation of a treatment for mRCC patients.